Recommended maximum intake of alcoholic beverages

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
목요일, 11월 9, 2023
Neoplasm, FDA, Research, Recommended maximum intake of alcoholic beverages, AACR, ATM, Food, Pembrolizumab, Endometrial cancer, Conference, Merck, PMV, KRAS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Poster, Pharmacokinetics, Clinical trial, KOL, Merck Sharp & Dohme Federal Credit Union, Mass, Safety, Patient, Breast, Prostate, Merck & Co., Pharmaceutical industry, Cryptocurrency, G&A

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • We look forward to initiating a registrational Phase 2 study in the first quarter of 2024.”
    Third Quarter 2023 and Recent Corporate Highlights:
    Updated clinical results from the Phase 1 PYNNACLE study evaluating PC14586 were featured in a late-breaking poster at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 12, 2023.
  • A copy of the poster can be found on the PMV corporate website here .
  • General and administrative (G&A) expenses were $18.7 million for the nine months ended September 30, 2023, compared to $18.9 million for the nine months ended September 30, 2022.

Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Retrieved on: 
수요일, 11월 8, 2023
Patient, Principal, Gynaecology, Masonic Cancer Center, Notifiable disease, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Ovarian cancer, Human, TGF, University, Professor, Inflammation, Gynecologic Oncology (journal), SITC, Immunotherapy, DL2, Disease, Division, NK, Cytokine release syndrome, DRS, Tumor microenvironment, Safety, Society, Recommended maximum intake of alcoholic beverages, Pharmaceutical industry, Medical imaging, Vaccine, Liver, Obstetrics, Cancer

MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. Data from this study was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) by Melissa A. Geller, M.D., M.S., Professor and Division Director of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Women’s Health at the University of Minnesota who serves as a Principal Investigator of this trial.

Key Points: 
  • The trial is now in its final expanded dose level, and the Company expects it to be completed in the fourth quarter of 2023.
  • There has been one dose-limiting toxicity experience in this study, but it did not trigger stopping rules.
  • In addition, we believe, perhaps even more importantly, their extensive correlative studies provide valuable evidence that will inform our Phase 2 clinical studies in cancer indications.
  • With these strong results as a foundation, we believe we will be in a position to pivot to initiate our first Phase 2 clinical trial this year.”

Needed Raises $14M to Champion a Radically Better Nutrition Standard for Women

Retrieved on: 
화요일, 11월 7, 2023
Research, Women, Finance, Baby, Maternity, Fitness & Nutrition, Professional Services, General Health, Consumer, Health, Science, Fertility, Female, Labs, Standard of care, Preterm birth, The Craftory, Education, Life, Pre-eclampsia, Infant, Multimedia, Trust, Gestational diabetes, Pregnancy, RDA, Women's health, Planet, Sleep, Woman, Lactation, Recommended maximum intake of alcoholic beverages, Dietary supplement

View the full release here: https://www.businesswire.com/news/home/20231107679237/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231107679237/en/
    Julie Sawaya and Ryan Woodbury, Needed co-founders and co-CEOs (Photo: Business Wire)
    Needed is known for its system of radically better, science-backed nutritional supplements for women in the perinatal stage.
  • “Nutrition is one of the most significant and most overlooked decisions made in the pregnancy journey,” said Julie Sawaya, Needed co-founder and co-CEO.
  • “However, nutrition is often relegated to an afterthought and women are left with more questions than answers about their nutritional needs.
  • Needed is setting a new, radically better standard for perinatal nutrition combining the products, education, and access to nutritional experts that all women need and deserve.”
    “Nutrition changes perinatal outcomes.

Angiex Announces FDA Clearance of IND Application for AGX101, a novel, First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Cancers

Retrieved on: 
목요일, 11월 2, 2023
FDA, IND, PD, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Drug development, Pharmacokinetics, ADC, Neoplasm, Biology, Safety, Cancer, Patient, Recommended maximum intake of alcoholic beverages, Investigational New Drug, Pharmaceutical industry

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers.
  • “Angiex also is pioneering a novel ability to release ADC payloads in the nucleus of target cells in the tumor.
  • The dose escalation portion of the study is designed to assess doses up to 10 mg/kg in an all-comers, solid tumor patient population.
  • The dose expansion portion of the study will evaluate treatment at the Recommended Phase 2 Dose in multiple indications.

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Retrieved on: 
일요일, 10월 22, 2023
MTD, Trial of the century, Plasma, Dana–Farber Cancer Institute, Half-life, Associate, ESMO, Progression-free survival, SERD, Congress, PFS, European Society for Medical Oncology, Circulating tumor DNA, Pharmacokinetics, ESR1, Division, Index, Webcast, Recurrence, Breast cancer, Oncology, CBR, Woman, ER, Fourth grade, Patient, Neoplasm, Fulvestrant, Recommended maximum intake of alcoholic beverages, Mutation, SAN, DNA, Road, Cryptocurrency, Pharmaceutical industry, Birth control

These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • “These Phase 2 monotherapy study results demonstrate that palazestrant (OP-1250) has the potential to become a best-in-class endocrine therapy and improve upon current standard of care treatments for women living with metastatic breast cancer.
  • In addition to being well-tolerated, palazestrant has demonstrated compelling progression-free survival as monotherapy in a heavily pretreated patient population,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • A copy of the oral presentation is available on Olema’s website under the Science section of the Olema website.

Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

Retrieved on: 
수요일, 6월 28, 2023
Maintenance, Diabetes, Progression-free survival, Maxima and minima, FTD, Survival, Cancer, Lung cancer, Fast Track, Toxicity, TUSC2, NSCLC, Index, Carboplatin, AstraZeneca, PFS, Non-small-cell lung cancer, Merck & Co., Etoposide, HIV disease progression rates, MD, Patient, MTD, Toxic leukoencephalopathy, Merck, Recommended maximum intake of alcoholic beverages, FDA, Pembrolizumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Disease, Pharmaceutical industry, Atezolizumab, SCLC

AUSTIN, Texas, June 28, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company's lead drug candidate, REQORSA® Immunogene Therapy, in combination with Genentech, Inc.'s Tecentriq® in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Key Points: 
  • We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC."
  • Virtually 100% of small cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein, and 41% completely lack TUSC2 protein expression.
  • "This Fast Track Designation for the Acclaim-3 patient population is another validation of REQORSA's potential to treat lung cancer," said Mark Berger, MD, Chief Medical Officer at Genprex.
  • In addition, Fast Track product candidates could be eligible for priority review if supported by clinical data at the time of BLA submission.

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

Retrieved on: 
목요일, 5월 11, 2023
DNA, ER, Circulating tumor DNA, Half-life, Metastasis, ESR1, DDI, Pharmacokinetics, Toxicity, Plasma, Incidence, Partial, Metabolism, Breast cancer, Data, SAN, Toxic leukoencephalopathy, Poster, Neoplasm, Recommended maximum intake of alcoholic beverages, SERD, Pharmaceutical industry, Phosphorus, Neutropenia, Patient

No dose-related increases in the incidence, severity, or timing of adverse events were observed, and neutropenia events observed were consistent with the expected profile of palbociclib plus endocrine therapy.

Key Points: 
  • No dose-related increases in the incidence, severity, or timing of adverse events were observed, and neutropenia events observed were consistent with the expected profile of palbociclib plus endocrine therapy.
  • Tumor responses and prolonged disease stabilization were observed in this group of patients, including in those previously exposed to palbociclib and other CDK4/6 inhibitors.
  • “We are very pleased with our emerging combination clinical results of OP-1250 with palbociclib,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • In a maturing dataset, anti-tumor activity and prolonged disease stabilization was demonstrated in patients previously treated with CDK4/6 inhibitors, including palbociclib.

Scale Media's 1MD Nutrition Brand Announces Launch of New CardioFitMD

Retrieved on: 
월요일, 1월 31, 2022
Entrepreneurship, Patient, Mineral, Water, Recommended maximum intake of alcoholic beverages, Vitamin, Face, GMO, E-commerce, Bacillus coagulans, Nutrition, Mental health, Ageing, Health, Letter, Nutritional science, RDI, Physical fitness, Essential elements of information, Heart, CPG, Beauty, Metabolism, Dietary supplement

LOS ANGELES, Jan.31, 2022 /PRNewswire-PRWeb/ --1MD Nutrition, a premier nutritional supplement brand powered by Scale Media , has just announced its launch of CardioFitMD.

Key Points: 
  • LOS ANGELES, Jan.31, 2022 /PRNewswire-PRWeb/ --1MD Nutrition, a premier nutritional supplement brand powered by Scale Media , has just announced its launch of CardioFitMD.
  • The 1MD Nutrition scientific research team partnered with interventional cardiologist, Dr. Heather Shenkman in the unique formulation of CardioFItMD.
  • Added Ziv Haklili , Co-Founder of 1MD Nutrition and Scale Media:
    "The last two years have forced most Americans to face unprecedented challenges, including nutritional, physical, and mental health.
  • Through their proprietary eCommerce and digital marketing engine, Scale transforms consumers' end-to-end online shopping experience while increasing brand loyalty and retention.

Winter's shorter days are here: Protect your bones

Retrieved on: 
목요일, 12월 2, 2021
Research, Patient, Man, U.S. News & World Report, RDA, Skin, Degenerative disease, Cushing's disease, Sunlight, Sports medicine, MOR, Crohn's disease, Smoking, NIH, Exercise, News, Vitamin D, Woman, Tobacco, Chicago Fire FC, Joffrey Ballet, Inflammation, Bone density, Rickets, Recommended maximum intake of alcoholic beverages, Egg, Bone loss, Dairy, Ius, Physician, Cheese, Chicago White Sox, Milk, Joint, Rush University Medical Center, Absorption, Daylight saving time, UVB, Tuna, Walking, Park Ridge, Food, Munster, Jogging, Chicago Bulls, Chicago Bulls (AFL, 1926), No, Osteoporosis, Salmon, Osteopenia, Calcium, Dietary supplement

Whiledarker days can be emotionally hard, they can also be hazardous to your bones due to a lack of vitamin D and exercise.

Key Points: 
  • Whiledarker days can be emotionally hard, they can also be hazardous to your bones due to a lack of vitamin D and exercise.
  • According to a NIH study , the amount of vitamin D we obtain from the sun is limited during the winter.
  • Experts agree that incorporating the following tips can promote year-round bone health:
    Bone cells are continuously replaced, so it is important to consume calcium to keep bones strong.
  • Good sources of calcium include dairy products, almonds, broccoli, kale, canned salmon with bones, sardines, and soy products, such as tofu.

Even 'Low-Risk' Drinking Can Be Harmful: Journal of Studies on Alcohol and Drugs

Retrieved on: 
월요일, 6월 15, 2020
Psychoactive drugs, Drinking culture, Health, Articles, Alcohol abuse, Alcoholism, Psychiatric diagnosis, RTT, Substance dependence, Alcoholic drink, Recommended maximum intake of alcoholic beverages, Alcohol education

PISCATAWAY, N.J., June 15, 2020 /PRNewswire/ --It's not just heavy drinking that's a problem -- even consuming alcohol within weekly low-risk drinking guidelines can result in hospitalization and death, according to a new study published in the Journal of Studies on Alcohol and Drugs.

Key Points: 
  • PISCATAWAY, N.J., June 15, 2020 /PRNewswire/ --It's not just heavy drinking that's a problem -- even consuming alcohol within weekly low-risk drinking guidelines can result in hospitalization and death, according to a new study published in the Journal of Studies on Alcohol and Drugs.
  • The Canadian government's low-risk drinking guidelines state that women should consume no more than about 10 drinks per week and men no more than 15.
  • For example, more than 50 percent of cancer deaths resulting from alcohol use occurred in people drinking moderately.
  • Overall, he says, the best advice for drinking is to err on the side of caution, "When it comes to alcohol use, less is better."